Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRX AcelRx Pharmaceuticals		$0.77	$0.43 ▼ $2.78	$14.58M	0.52	137,683 shs	243,500 shs
HAPP Happiness Development Group	$0.69	$0.84	$2.08 ▼ $7.40	$4.80M	0.23	14,340 shs	202 shs
SLNO Soleno Therapeutics	$67.68 -2.8%	$81.56	$41.50 ▼ $90.32	$3.60B	-2.56	1.13 million shs	1.07 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRX AcelRx Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
HAPP Happiness Development Group	0.00%	-9.80%	-21.61%	-31.68%	-33.01%
SLNO Soleno Therapeutics	+4.66%	+4.19%	-19.50%	-8.13%	+50.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HAPP Happiness Development Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLNO Soleno Therapeutics	4.5659 of 5 stars	4.5	1.0	0.0	4.6	2.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRX AcelRx Pharmaceuticals	0.00	N/A	N/A	N/A
HAPP Happiness Development Group	0.00	N/A	N/A	N/A
SLNO Soleno Therapeutics	3.08	Buy	$115.09	70.05% Upside

Current Analyst Ratings Breakdown

Latest ACRX, HAPP, and SLNO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	SLNO Soleno Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$106.00
8/20/2025	SLNO Soleno Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$123.00
8/18/2025	SLNO Soleno Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $110.00
8/7/2025	SLNO Soleno Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/7/2025	SLNO Soleno Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$97.00 ➝ $106.00
8/7/2025	SLNO Soleno Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$105.00 ➝ $110.00
7/11/2025	SLNO Soleno Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$105.00 ➝ $121.00
6/23/2025	SLNO Soleno Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/23/2025	SLNO Soleno Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$110.00

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRX AcelRx Pharmaceuticals	$1.77M	0.00	N/A	N/A	$2.65 per share	0.00
HAPP Happiness Development Group	$95.59M	0.05	N/A	N/A	$19.57 per share	0.04
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	$4.52 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRX AcelRx Pharmaceuticals	$47.76M	-$2.23	N/A	N/A	N/A	N/A	-81.54%	-46.02%	N/A
HAPP Happiness Development Group	-$49.19M	$0.48	1.44	∞	N/A	N/A	N/A	N/A	N/A
SLNO Soleno Therapeutics	-$175.85M	-$4.14	N/A	N/A	N/A	N/A	-73.74%	-56.67%	11/5/2025 (Estimated)

Latest ACRX, HAPP, and SLNO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	SLNO Soleno Therapeutics	-$0.53	-$0.09	+$0.44	-$0.09	$3.91 million	$32.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRX AcelRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HAPP Happiness Development Group	N/A	N/A	N/A	N/A	N/A
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRX AcelRx Pharmaceuticals	N/A	4.04	4.04
HAPP Happiness Development Group	N/A	2.01	1.94
SLNO Soleno Therapeutics	0.21	15.13	15.01

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRX AcelRx Pharmaceuticals	19.79%
HAPP Happiness Development Group	15.22%
SLNO Soleno Therapeutics	97.42%

Insider Ownership

Company	Insider Ownership
ACRX AcelRx Pharmaceuticals	3.00%
HAPP Happiness Development Group	15.58%
SLNO Soleno Therapeutics	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRX AcelRx Pharmaceuticals	19	16.95 million	16.44 million	Optionable
HAPP Happiness Development Group	215	6.96 million	5.87 million	Not Optionable
SLNO Soleno Therapeutics	30	53.15 million	49.74 million	Optionable

ACRX, HAPP, and SLNO Headlines

Recent News About These Companies

Soleno Therapeutics Meets 80-Plus Relative Strength Rating Benchmark

August 27 at 10:44 AM | msn.com

Soleno Therapeutics to Participate in Upcoming September Conferences

August 27 at 8:00 AM | globenewswire.com

Price T Rowe Associates Inc. MD Grows Stake in Soleno Therapeutics, Inc. $SLNO

August 27 at 5:03 AM | marketbeat.com

Hsbc Holdings PLC Acquires New Stake in Soleno Therapeutics, Inc. $SLNO

August 27 at 4:12 AM | marketbeat.com

Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman

August 26 at 4:22 PM | globenewswire.com

SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm

August 26 at 4:15 PM | globenewswire.com

Wellington Management Group LLP Has $49.56 Million Stake in Soleno Therapeutics, Inc. $SLNO

August 26 at 4:15 AM | marketbeat.com

Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO

August 25 at 12:23 AM | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

August 25 at 10:00 PM | prnewswire.com

Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SLNO

August 25 at 3:11 PM | mms.businesswire.com

Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SLNO

August 25 at 3:01 PM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

August 25 at 11:33 AM | globenewswire.com

Resolute Capital Asset Partners LLC Purchases Shares of 40,000 Soleno Therapeutics, Inc. $SLNO

August 25 at 7:35 AM | marketbeat.com

Vanguard Group Inc. Has $133.35 Million Stock Holdings in Soleno Therapeutics, Inc. $SLNO

August 24 at 3:17 AM | marketbeat.com

Soleno Therapeutics, Inc. $SLNO Shares Bought by Swiss National Bank

August 23, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

August 22, 2025 | prnewswire.com

Wells Fargo & Company Begins Coverage on Soleno Therapeutics (NASDAQ:SLNO)

August 22, 2025 | marketbeat.com

Research Analysts Set Expectations for SLNO Q3 Earnings

August 22, 2025 | marketbeat.com

Wells Fargo Initiates Coverage of Soleno Therapeutics (SLNO) with Overweight Recommendation

August 21, 2025 | msn.com

Soleno Therapeutics (NASDAQ:SLNO) Now Covered by Analysts at Wells Fargo & Company

August 21, 2025 | americanbankingnews.com

Q3 EPS Forecast for Soleno Therapeutics Boosted by Analyst

August 21, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ACRX, HAPP, and SLNO Company Descriptions

AcelRx Pharmaceuticals NASDAQ:ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

Happiness Development Group NASDAQ:HAPP

$0.69 0.00 (0.00%)

As of 08/25/2025

Happiness Development Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It also offers product marketing and e-commerce agency operation services under the Happy Buy platform to small and middle size businesses; and e-commerce solutions, internet information, and advertising services to the online stores or manufactures. In addition, the company provides secure transaction environment, automobile procurement, and financial services for automobile manufacturers under the Taochejun automobile sales platform. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. The company was formerly known as Happiness Biotech Group Limited and changed its name to Happiness Development Group Limited in October 2022. Happiness Development Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.

Soleno Therapeutics NASDAQ:SLNO

$67.68 -1.93 (-2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$67.63 -0.05 (-0.07%)

As of 04:20 PM Eastern

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time